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ABSTRACT: Toll-like receptors (TLRs) are key pathogen sensors of
the immune system. Their activation results in the production of
cytokines, chemokines, and costimulatory molecules that are crucial for
innate and adaptive immune responses. In recent years, specific (sub)-
cellular location and timing of TLR activation have emerged as
parameters for defining the signaling outcome and magnitude. To study
the subtlety of this signaling, we here report a new molecular tool to
control the activation of TLR2 via “click-to-release”-chemistry. We
conjugated a bioorthogonal trans-cyclooctene (TCO) protecting group
via solid support to a critical position within a synthetic TLR2/6 ligand
to render the compound unable to initiate signaling. The TCO-group
could then be conditionally removed upon addition of a tetrazine,
resulting in restored agonist activity and TLR2 activation. This approach was validated on RAW264.7 macrophages and various
murine primary immune cells as well as human cell line systems, demonstrating that TCO-caging constitutes a versatile approach for
generating chemically controllable TLR2 agonists.
Toll-like receptors (TLRs) play a pivotal role in the(innate) immune system. Upon recognition of conserved
microbial structures, TLRs dimerize and induce signaling
events that culminate in the production of cytokines,
chemokines, and costimulatory molecules.1 These serve both
to directly combat infection and to attract and activate other
cells of the innate and adaptive immune system.2 For this
reason, synthetic TLR agonists are potent therapeutic
compounds for preventing/treating infections3,4 but also for
boosting anticancer immune responses.5 Excessive TLR-
induced inflammation can, however, have deleterious effects.
Infection-associated sepsis6 and inflammatory and auto-
immune diseases, such as asthma7 and systemic lupus
erythematosus (SLE),8 are marked by aberrant TLR-signaling.
Thus, a detailed understanding of the processes that shape the
outcome of TLR signaling is required for the rational design of
novel therapeutics that elicit beneficial effects while preventing
immune pathogenesis.
Over the past decade, it has become apparent that TLRs
display complex, dynamic behavior within (immune) cells.9
The specific (sub)cellular locations where these receptors can
be activated are tightly controlled. For example, the intra-
cellular TLRs 3, 7, 8, and 9 are produced as inactive precursors
that are processed locally in endolysosomal vesicles by pH-
sensitive proteases. This ensures they can only engage ligands
at this specific location.10−13 Additionally, different signaling
outcomes may be realized from distinct cellular sites, as
exemplified by TLR4: when ligated at the cell surface, TLR4
assembles a signaling platform via the adaptor protein MyD88
to induce the activation of the transcription factors nuclear
factor-κB (NF-κB) and activator protein-1 (AP-1).14 This
results in the expression of pro-inflammatory cytokines and
chemokines. When, on the other hand, for the same receptor
signals from an endosome,15 it uses the adaptor protein TRIF
to induce the activation of interferon regulatory factors
(IRFs),16 which in turn initiates the production of antiviral
type I interferons (IFN-I). For the cell-surface resident TLR2,
location-specific signaling outcomes have also been re-
ported,17−19 although the signaling dynamics and their relation
to immune activation appear less well understood.
To study this complexity of signaling properly, specialized
chemical tools have been developed that allow controlled
induction of TLR activation. For example, biotinylated TLR-
ligands immobilized on surfaces have been used to spatially
restrict signaling of the receptor to the cell surface.20
Photolabile protecting groups introduced to key residues on
TLR-agonists have been used to control the signaling of the
receptor in time. Upon UV-irradiation, the protecting group
Received: April 19, 2020
Revised: May 27, 2020
Published: June 8, 2020
Articlepubs.acs.org/bc
© 2020 American Chemical Society
1685
https://dx.doi.org/10.1021/acs.bioconjchem.0c00237
Bioconjugate Chem. 2020, 31, 1685−1692
This is an open access article published under a Creative Commons Non-Commercial No
Derivative Works (CC-BY-NC-ND) Attribution License, which permits copying and




















































































can be removed to initiate TLR binding and signaling.21−25
Potential drawbacks of this photochemistry based approach,
include the induction of phototoxicity as well as the limited in
vivo tissue penetrance of UV-light.
Bioorthogonal protection/deprotection strategies can offer a
solution here. By using protecting groups that can be
selectively removed with nontoxic chemical reagents, the
above limitations can be circumvented. For such a reaction to
be of use, it has to be fast, nontoxic, and synthetic access to the
reagents must be feasible.26,27 One reaction that meets these
requirements is the inverse electron-demand Diels−Alder
(IEDDA)/pyridazine elimination tandem reaction between a
2-substituted trans-cyclooctene (2-TCO) and a tetrazine, a so-
called “click-to-release”-reaction (C2R).28 Reactivity of TCO
toward tetrazines originates from the high degree of ring strain
induced by the trans-configuration of the olefin.29 After a [4 +
2] cycloaddition, 4,5-dihydropyridazine is formed while
expelling nitrogen in the process.28 This is followed by a
tautomerization to liberate the carbamate functionality, which
quickly decarboxylates to release a free amine functional group
and carbon dioxide (Figure 1). The above C2R-reaction has
gained popularity due to its rapid ligation and elimination
kinetics30−32 and has found use in antibody-drug conju-
gates,33,34 protein activation,35,36 RNA synthesis,37 and on-
demand T-cell activation.38 Furthermore, tetrazine doses
required for inducing this reaction are nontoxic, thus,
permitting studies even in live animals.33,34,36,38 The speed of
the reaction drives TCO-elimination in an almost instanta-
neous “switch-like” manner, which is of crucial importance
when investigating the complex kinetics of receptor signal-
ing.31,32
Here, we set out to develop a C2R-approach for condition-
ally controlling the activation of TLRs. We focused on TLR2
(Figure 1), because many of its downstream signaling
properties remain to be elucidated. While most TLRs form
homodimers upon ligation, TLR2 forms heterodimer com-
plexes with TLR1 or TLR6, each having distinct ligand-binding
specificities.40 We conjugated TCO to a known TLR2/6
agonist in such a way that it obstructs receptor heterodime-
rization, so that only after elimination of the protecting group
by a tetrazine, receptor dimerization can take place, leading to
the induction of inflammatory signaling (Figure 1). We
investigated the use of this approach for studying the kinetics
of TLR2/6 activation as well as the cytokine profile after
activation. The low toxicity of this approach allows the study of
these processes in model cell lines but also in primary immune
cells.
■ RESULTS AND DISCUSSION
One of the best-defined synthetic TLR2/6 agonists is
Pam2CSK4 (P2K4), for which both a crystal structure of the
ligand bound to murine TLR2/TLR639 and extensive
structure−activity relationship (SAR) data41 are available.
The two palmitoyl tails of P2K4 strongly bind in a hydrophobic
pocket of TLR2, whereas the Cys-Ser amide bond engages in a
hydrogen bond with TLR6.
Substitution of the N-terminus diminishes ligand activity,
likely through disrupting TLR2/6 dimerization, while main-
taining strong binding to TLR2.23 The amine-residue critical to
this interaction is therefore an ideal conjugation site for a
bioorthogonal protecting group.
Synthesis of the Unmodified and TCO-Caged TLR2/6
Ligand P2K4. To explore inverse electron-demand Diels−
Alder (IEDDA)/pyridazine (de)protection as an approach for
the guided activation of TLR2, we synthesized both a TCO-
caged derivative of P2K4 (4, Scheme 1) as well as an uncapped
Figure 1. Schematic of conditionally inducing TLR2 activation via
“click-to-release” chemistry. Signaling via TLR2/6 by an agonist
protected with trans-cyclooctene (TCO, indicated in red) is
selectively induced after a tetrazine is applied to remove the caging
moiety. Figure is based on the crystal structure of TLR2/6.39 X = Lys4
or TEG.
Scheme 1. Synthesis of TCO-Protected Pam2CSK4-
Analoguea
a(a) Fmoc-Lys(Mtt)−OH, DIC, DMAP, rt; (b) HCTU-mediated
SPPS, rt; (c) (1) 20% piperidine, DMF, rt; (2) Compound 1, HCTU,
DiPEA, rt; (3) 20% piperidine in DMF, rt; (d) Compound 2, DiPEA,
rt; (e) 5% TFA, 1% TIS, 1% H2O in DCM, rt.
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control (3, Scheme 1). Synthesis was performed on the
Tentagel S AC resin. The serine side chain was protected as a
trityl (Trt) ether, while lysine side chains were protected with
4-methyltrityl (Mtt) to enable the full deprotection and resin-
cleavage of products under dilute TFA conditions. This was
necessary due to TCO’s propensity to isomerize under acidic
conditions.42 Pure building block 1, with the central carbon in
the diacylglycerol group R-configured, was used as the activity
of the S-isomer is significantly lower.43 The TCO-caged ligand
was obtained after reaction with 2. Compounds 3 and 4 were
then cleaved from the solid support using a mixture of 5% TFA
in DCM, thereby minimizing TCO isomerization, followed by
HPLC purification.
Activity of the TCO-Caged TLR2 Ligand Is Sup-
pressed and Is Restored upon Applying a Chemical
Deprotection Agent. To assess whether protection of the
critical amine in P2K4 as a TCO-carbamate rendered the
compound unable to activate TLR2/6-signaling, the murine
macrophage cell line RAW264.7 was treated with 4 (Figure 2A,
control) and as a measure of TLR2 activation, nuclear
translocation of the transcription factor NF-κB was visualized
using confocal microscopy. Cells treated with 4 exhibited no
nuclear translocation of NF-κB, indicating that the TCO-cage
prevents TLR2 activation (Figure 2B). Next, we determined
whether removal of the protecting group could restore agonist
activity. Upon addition of 10 μM 3-methyl-6-pyrimidylte-
trazine (Tz)44 to cells pretreated with 4 (Figure 2A, + Tz),
nuclear NF-κB was detected after 30 min (Figure 2B),
indicating that P2K4 was liberated by the added Tz to induce
TLR2 signaling.
To further evaluate the effect of TCO-deprotection,
downstream transcriptional activity of NF-κB was assessed
using the commercially available RAW-Blue reporter cell line.
These cells produce secreted embryonic alkaline phosphatase
(SEAP) expressed from an NF-κB inducible promoter. Cells
were treated with the TCO-caged compound 4 as above or
with control compound 3. After 24 h, SEAP levels were
determined in the culture supernatant using a colorimetric
assay. Cells treated with 0.01−1 nM 4 displayed marginal
levels of NF-κB activity compared to cells stimulated with the
free ligand 3 (Figure 2C, dark green bars compared to blue
line). Only at a high ligand dose (10 nM), the caged ligand did
induce some residual activity. The chemical trigger Tz restored
compound 4-induced NF-κB-SEAP levels to those of cells
treated with 3 (Figure 2C, bright green bars compared to blue
line), whereas NF-κB-SEAP was not induced when treating
cells with Tz alone. These data confirm that Tz-induced ligand
uncaging restores the agonist activity of 4 and that this
translates to TLR2 activation and a cellular response.
Next, we assessed whether conditionally controlled TLR2
activation resulted in the production of downstream
inflammatory mediators in primary bone marrow derived
macrophages (BMDMs) and bone marrow derived dendritic
cells (BMDCs) (Figure 2D,E and 3A). When treated with 4,
both types of innate immune cells selectively secreted the NF-
κB-induced cytokine tumor necrosis factor-α (TNFα) when
the agonist was liberated using Tz (Figure 2D and 3A).
Additionally, compound 4-treated BMDMs selectively upregu-
lated the macrophage activation marker F4/80 after uncaging
(Figure 2E). To exclude the aspecific induction of inflamma-
tory mediators, for instance due to cellular stress, we confirmed
that 4 did not induce TNFα production under uncaging
conditions in TLR2 knockout (ΔTLR2) BMDMs and
BMDCs, even at high ligand doses (Figure S2). For CD11c+
splenic DCs that were directly treated ex vivo, conditionally
controlled TNFα, and interleukin-6 (IL-6) production was
observed (Figure 3B,C), demonstrating the robustness of the
TCO-(un)caging strategy for use in murine cell lines,
differentiated immune cells, and primary cells upon treatment
with 4 and Tz.
These combined findings illustrate that TCO is a suitable
cage for inhibiting mouse TLR2/6 ligand activity and that
tetrazine-induced uncaging sufficiently recovers agonist activity
to induce TLR2 signaling. This confirms the potential of the
IEDDA/pyridazine elimination tandem reaction to condition-
ally control TLR2 activation.
Figure 2. Controlling the activity of murine TLR2 with TCO-caged
P2K4 on macrophages: (A) experimental outline for conditionally
controlling TLR2 activity. After a 45−60 min preincubation of cells
with the caged ligand, medium is replaced with tetrazine (Tz)-
containing medium. This triggers rapid removal of the protecting
group, thereby restoring agonist activity and resulting in TLR2-
induced NF-κB activation. (B) RAW-Blue macrophages were fixed
after 30 min and stained for the NF-κB subunit p65 (in red). (C)
Levels of NF-κB-induced SEAP in the culture supernatant of RAW-
Blue reporter cells 24 h after Tz treatment. (D) Conditionally induced
TNFα by BMDMs as surveyed by ELISA of culture supernatant 6 h
after Tz treatment. ND not detected; NS, not significant; **, p < 0.01
(Students t test). Purity checks of the cell cultures used for are
provided in Figure S1. Data are representative of one (B and C), two
(E), or four (D) independent experiments.
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Substantial Residual Activity of the TCO-Caged TLR2
Ligand Limits Its Use in Human Cells. Recently, a number
of striking differences have been reported in the molecular
mechanisms employed by mouse and human TLR2 to
transduce signals18 (manuscript under review). To study the
complexity of human TLR2 signaling it is, therefore, important
that chemical tools are also applicable in human cells. We
therefore evaluated the conditional induction of human TLR2
activity with 4 next.
We treated human TLR2-expressing melanoma cell line
MelJuso as above and visualized NF-κB localization. Nuclear
NF-κB levels were clearly enriched after 10 μM Tz treatment
for all ligand doses tested (Figure 4A), demonstrating that, also
in human cells, uncaging of 4 results in enhanced TLR2
activity. We, however, detected considerable amounts of
nuclear NF-κB in cells treated only with the caged compound.
To exclude TLR2 overexpression related or cell type-specific
artifacts, we next employed the human monocyte reporter cell
line THP1-Dual (Invivogen), which expresses NF-κB-inducible
SEAP, analogous to the above mouse reporter macrophages.
TLR2-induced NF-κB activity was confirmed for 3 and Tz-
treatment restored SEAP induction by THP1-Dual cells
treated with 4 to the levels induced by 3 (Figure 4B). Yet,
also in these immune cells, we observed marked residual
activity of the caged compound for doses ≥0.1 nM.
The combined data suggest that, while Tz-induced uncaging
of 4 conditionally induces human TLR2 activity, its
experimental use in human cells is limited due to residual
activity exerted by the protected compound. Only at low doses
(≤0.01 nM) did compound 4 not induce substantial TLR2
activation. However, at these doses, NF-κB is suboptimally
activated after ligand deprotection, evidenced by a limited
number of cells showing modest levels of NF-κB nuclear
translocation (Figure 4A) and low NF-κB-reporter levels
(Figure 4B). We hypothesized that the discrepancy between
our mouse and human TLR2 data (Figures 2−4) resulted from
structural differences at TLR2 sites important for ligand
binding,45 leading to altered ligand specificities and affinities.46
We, therefore, next attempted to redesign the TCO-caged
TLR2 ligand so that it would robustly induce NF-κB activation
Figure 3. Controlling the activity of murine TLR2 with TCO-caged
P2K4 on dendritic cells: (A−C) Dendritic cells were treated as
described in Figure 2A, and conditionally induced TNFα or IL6
production was surveyed by ELISA in culture supernatant 6 h (A) or
16 h (B,C) after Tz treatment. ND not detected; NS, not significant;
*, p < 0.05; **, p < 0.01 (Students t test). Because BMDCs and
CD11c+ splenic DCs responded to the free, noncapped compound 3
with different sensitivities compared to BMDMs, different (indicated)
doses were used to yield robust TLR2 responses. Purity checks of the
cell cultures used for are provided in Figure S1. Data are
representative of four (A) or two (B and C) independent
experiments.
Figure 4. Substantial residual activity induced by TCO-caged
P2K4hampers experiments with human cells. (A) MelJuso TLR2-
YFP cells were fixed 30 min after ligand uncaging was induced and
stained for the NF-κB subunit p65 (in red). (B) NF-κB-SEAP levels in
the culture supernatant of THP1-Dual monocytes 24 h after
conditionally inducing TLR2 activation. Data are representative of
two (A) or three (B) independent experiments and cells were treated
as described in Figure 2A.
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in human cells with a better signal-to-noise ratio over a broad
concentration range.
Design and Synthesis of a Human-TLR2/6-Compat-
ible Caged Ligand. We opted to increase the steric bulk of
the TCO-cage, to assess whether this could better prevent
receptor dimerization in human cells. For this, we used a
bifunctional TCO-group (6, Scheme 2),33 enabling the
introduction of a bulky hydrophilic substituent at the second
modification site. The small protein ubiquitin (Ub) was
conjugated to this position, in view of its favorable properties:
it is an 8.6 kDa water-soluble, accessible, and thermally stable
protein. Conjugating such a large molecule to an activated
ester on solid phase often suffers from extremely low coupling
efficiencies. Hence, we opted for a solution-phase coupling
strategy.
Deprotection of the lysine residues of P2K4 after protein
conjugation in a solution-phase strategy, while abstaining from
using acid- or base-labile protecting groups, quickly leads to
complex synthetic routes. In contrast to the lipidated CysSer
dipeptide motif, the C-terminal lysine residues of the agonist
are not crucial for inducing TLR2 activation39 and substitution
of the K4-tail with ethylene glycols has previously been shown
to be tolerated.47 We, therefore, chose to replace the K4-tail of
P2K4 with triethylene glycol (TEG), to facilitate the synthesis
of a Ub-TCO-caged TLR2/6 ligand (compound 9, Scheme 2).
For comparison, we also synthesized the free, noncapped (7)
and TCO-caged (8) Pam2CSTEG (P2TEG) equivalents. The
ability of compound 8 to react with tetrazine was confirmed in
an LC-MS experiment (Figure S8).
Analogous to the synthesis of compound 3, compound 7 was
synthesized on resin for ease of purification of the
intermediates. After cleavage from the resin, 7 was purified
using RP-HPLC. Compound 7 was then treated with either
TCO-OSu (2) or bis-functionalized TCO (6) in solution
phase. After LC-MS indicated complete consumption of
compound 7, the mixture was added to a solution of ubiquitin
in DMSO. After having stirred the reaction for 7 days, HRMS
indicated the formation of a ubiquitin conjugate containing
one, two, or three ligands. Interestingly, HPLC purification of
compound 9 led to the isolation of two separate fractions both
containing a compound with the molecular mass of a singly
conjugated product. Since ubiquitin contains seven lysine
residues as well as a free N-terminus, different isoforms can be
expected to form. Both fractions were tested in biological
assays and are referred to as fraction A or fraction B in the
Supporting Information.
TCO-Caged P2TEG Shows Enhanced Performance in
Human Cells. The P2TEG-derived constructs (7−9) were
tested in the THP1-Dual reporter cell system along with 4
(Figure 5). Both collected fractions of compound 9 gave
similar results (Figure S3A) and, therefore, only fraction A is
used in Figure 5. The activity of both compounds 8 and 9 was
induced by Tz, resulting in robust expression of the NF-κB-
SEAP reporter (Figure 5). Generally, higher doses of the
P2TEG-derived compounds were required for eliciting similar
levels of NF-κB activity. This was true both for the deprotected
(Figure 5) and free, noncapped ligands (Figure S3B). The Ub-
TCO-modified 9 displayed much lower residual activity
compared to 4.
Surprisingly, 8 also induced comparably low levels of basal
activity, despite the absence of a bulky TCO-substituent,
yielding a good signal-to-noise ratio of NF-κB activity in the
1−10 nM concentration range (Figure 5). This suggests that
the nonextended TCO sufficed to prevent receptor dimeriza-
tion and that the K4-tail of compound 4 was the source of the
Scheme 2. Synthesis of Human TLR2/6 Compatible Caged
Ligandsa
a(a) Compound 5, DIC, DMAP, rt; (b) (1) 20% piperidine in DMF,
rt; (2) Fmoc-Ser(OTrt)−OH, HCTU, DiPEA, rt; (3) 20% piperidine
in DMF, rt; (c) (1) compound 1, HCTU, DiPEA, rt; (2) 20%
piperidine in DMF, rt; (d) 20% TFA, 2.5% TIS, 2.5% H2O in DCM,
rt; (e) compound 2, DiPEA, rt; (f) (1) compound 6, DiPEA, rt; (2)
ubiquitin, DiPEA in DMSO, rt.
Figure 5. Substitution of the K4-tail with triethylene glycol (TEG)
substantially reduces basal activity of the caged TLR2 ligands in
human cells, which is not further improved by extensions on the
TCO-cage. THP1-Dual reporter cells were treated as described in
Figure 2A and, after 24 h, the level of SEAP in the culture supernatant
was determined as a measure of NF-κB activity. Data are
representative of three independent experiments (whereof twice
including compound 9).
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background activity. The reason for this remains unelucidated.
The K4-tail, but not the TEG, might provide modest
opportunistic interactions that stabilize the TLR2/TLR6
receptor dimer,39 counteracting the protecting capacity of
the TCO-cage. Nevertheless, 8 clearly is the preferred ligand
for conditionally controlling human TLR2 signaling. Taken
together, our data reveal that TCO-P2TEG (8) is a more
suitable caged ligand for controlling human TLR2 activation
than TCO-P2K4 (4), because it exerts potent inflammatory
activity when deprotected without eliciting residual activity
when protected.
Reaction Rate of Click-to-Release Uncaging Does Not
Delay Immune Activation. Thus far, we have mainly
focused on the efficacy of TCO as a chemical cage in terms
of reducing and restoring signaling amplitude rather than the
timing of receptor activation upon adding Tz. For precise
temporal control of TLR2 activation, the uncaging reaction
should occur rapidly, without causing an observable delay in
dimerization-induced signaling, providing a “switch-like”
activation upon adding the uncaging trigger.
To measure the time needed to induce TLR2 signaling
events upon uncaging the ligand, we surveyed TLR2-induced
nuclear translocation of NF-κB over time. To this end, we
performed live-cell imaging experiments on human TLR2+
MelJuso cells that stably express a fluorescently labeled subunit
of NF-κB (p65-RFP). As expected from the above results,
treatment of cells with 10 nM of 7 resulted in a time
dependent nuclear accumulation of NF-κB, whereas treatment
with 8 did not (Figure 6A). Addition of Tz and continued
imaging of the cells treated with 8 now revealed nuclear
translocation of NF-κB (Figure 6A).
For quantification purposes, t = 0 was defined as the time
when either free ligand was added to cells or when the
uncaging reagent Tz was added to cells that had been
pretreated with caged compound 8. This resulted in a similar
temporal pattern of NF-κB translocation in both settings
(Figure 6B). The levels of NF-κB in individual nuclei were
analyzed over time (supplementary video). Compared to cells
stimulated with free ligand 7, no delay was detected in the
speed with which nuclear NF-κB starts to accumulate after
triggering uncaging of 8 (Figure 6C). These data suggest that
elimination of the TCO-cage occurs negligibly fast in human
cells. Typical ligation kinetics are on the order of 103 M−1
s−131,48 and consequent elimination can proceed with a
reaction constant of 0.06 s−1 (t1/2 = 13 s) at physiological
pH.31,32 It should be noted that full recovery of agonist is likely
not required for the induction of TLR2 signaling, meaning that
the kinetics of NF-κB nuclear translocation may not accurately
reflect the true uncaging kinetics. Still, the data illustrate the
power of the Tz-induced “click-to-release” reaction for
triggering the near-instantaneous activation of TLR2 in cells
pretreated with TCO-P2TEG, making this (un)caging strategy
extremely powerful for precisely controlling TLR2 activation.
■ CONCLUSIONS
In conclusion, we have shown trans-cyclooctene to be a
suitable cage for preventing receptor activation when
conjugated to a synthetic TLR2/6 agonist. We demonstrated
that the activity of TCO-caged P2K4 could be restored upon
adding a tetrazine as an external trigger, which deprotects the
ligand through a C2R-reaction. The conditional induction of
TLR2 responses was validated in various murine cell types,
including ex vivo primary CD11c+ DCs. Substitution of the
terminal lysines of the prototypical agonist P2K4 for a TEG
yielded an easier to synthesize TCO-caged ligand with
improved performance in human cells. Additionally, we
showed that the kinetics of the uncaging reaction do not
induce a detectable delay in TLR2 signaling, allowing temporal
control over its activity. This methodology is not restricted to
the TLR2/6 complex and may therefore also find its use for
other pattern recognition receptors. Particularly suitable
Figure 6. Tetrazine restores the activity of caged TLR2 ligands
rapidly, without delaying NF-κB nuclear translocation kinetics. (A−
C) Live cell imaging of MelJuso TLR2-YFP p65-RFP cells. (A) Cells
were simultaneously treated with indicated compounds and imaged
for 50 min. Subsequently, tetrazine (Tz, 10 μM) was added to the
culture medium, and the same cells were imaged for an additional 50
min. (B,C) Cells were imaged after adding Tz (10 μM) to cells
preincubated with 10 nM TCO-P2TEG or after stimulation with
P2TEG. (B) Representative images of induced nuclear translocation
of p65-RFP (in red) over time. (C) For individual cells, nuclear
accumulation of NF-κB was tracked over time: left, fold increase in
nuclear p65-RFP fluorescence signal; right, normalized intensity of
nuclear p65-RFP, relative to the maximum signal intensity observed.
Quantification was performed on data from five independent
experiments. (A,B) To indicate nuclei, overlays with Hoechst (in
blue) are depicted.
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agonists for chemical caging have a low IC50 and are well-
soluble in aqueous solutions to ensure fast and complete
deprotection via tetrazines. We foresee that the described
IEDDA/pyridazine elimination strategy can form the basis of a
chemical toolset for unraveling the complex spatial and
temporal aspects of TLR signaling. Future work will aim at
developing tetrazine derivatives to impose spatial control by
directing the uncaging reagent to specific (sub)cellular sites.
Controlling when and where TLRs are activated in cells will
provide valuable insight into the complex spatiotemporal
patterns of TLR regulation. A better understanding of the
dynamic cellular processes that regulate TLR signaling may
provide important therapeutic opportunities for modulating
the (innate) immune responses, to combat infection or tumors,
while preventing damage to the host due to destructive
overinflammation.
■ MATERIALS AND METHODS
Detailed methods are described in the Supporting Information.
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